Greenwich LifeSciences has a Cash Ratio of 14.12. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Greenwich LifeSciences's Cash Ratio or its related term are showing as below:
GLSI'
s Cash Ratio Range Over the Past 10 Years
Min: 0.01 Med: 45.18 Max: 81.92
Current: 14.12
During the past 6 years, Greenwich LifeSciences's highest Cash Ratio was 81.92. The lowest was 0.01. And the median was 45.18.
GLSI's Cash Ratio is ranked better than 87.87% of 1476
companies
in the Biotechnology industry
Industry Median: 3.025
vs GLSI: 14.12
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Greenwich LifeSciences's Cash Ratio
For the Biotechnology subindustry, Greenwich LifeSciences's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Greenwich LifeSciences's Cash Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Greenwich LifeSciences's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Greenwich LifeSciences's Cash Ratio falls into.
Greenwich LifeSciences Cash Ratio Calculation
The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.
Greenwich LifeSciences's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Greenwich LifeSciences (NAS:GLSI) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Greenwich LifeSciences Cash Ratio Related Terms
Thank you for viewing the detailed overview of Greenwich LifeSciences's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Greenwich LifeSciences (Greenwich LifeSciences) Business Description
Greenwich LifeSciences Inc is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Its Product Candidates include; GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers, GM-CSF Immunoadjuvant has been shown to enhance monocyte and neutrophil cytotoxicity against melanoma tumor cells and to enhance activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies, and Cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells in order to inhibit the spread of cancer.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GLSI has been successfully added to your 